Newsletter SignupSearch

Board of Directors

About Us
Meet our board of directors, comprised of world-class experts and leaders who provide valuable guidance to our organization.

Magali Haas, MD, PhD
Board Chair

View Bio

Magali Haas, MD, PhD

Board Chair

Dr. Haas is Chair, CEO and President of Cohen Veterans Bioscience, a non-profit brain research organization based in New York City whose mission is to fast-track diagnostics and therapeutics to advance precision brain health. Magali has over 15 years of pharmaceutical executive experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in early and late stage neuroscience clinical development, translational medicine, diagnostics and integrative solutions. To pioneer new approaches for precision therapeutics for brain health, she founded Orion Bionetworks in 2012, which was transformed to Cohen Veterans Bioscience in 2015, while also serving as founding Chief Science and Technology Officer for One Mind for Research. She serves on several advisory boards including Alto Neurosciences, Partnership for Assessment and Accreditation of Scientific Practice, VirtualBrainCloud, Krembil Centre for Neuroinformatics and IMEC for nanoelectronics. Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, and her MD and PhD in neuroscience with distinction from Albert Einstein College of Medicine.

Michael Sullivan
Board Treasurer

View Bio

Michael Sullivan

Board Treasurer

Michael C. Sullivan is the Chief of Staff and Head of External Affairs of Point72 Asset Management. Mr. Sullivan joined the Firm in 2007 after serving as a senior aide in the United States Senate, focusing on telecom, technology, and finance issues. Mr. Sullivan also served as a staff member in the U.S. House of Representatives working on similar issues. Before coming to Capitol Hill, Mr. Sullivan was the head of strategic development for a telecommunications focused trade association.

Mr. Sullivan is involved with several veterans’ mental health-related non-profit organizations. He helped establish and serves on the Board and as Treasurer of the Cohen Veterans Network, which operates a national network of clinics to treat veterans and their family members affected by Post-Traumatic Stress. Mr. Sullivan also serves as the Treasurer and on the Board of a second veterans-oriented non-profit, Cohen Veterans Bioscience, which is developing next-generation diagnostics and therapeutics to improve the detection and treatment of Post-Traumatic Stress.

Mr. Sullivan is an Associate at the NYU-Stern Endless Frontier Labs, where he mentors start-up companies in artificial intelligence, machine learning, and related fields. He is also a member of the Executive Committee of Students First New York, a nonprofit organization advocating for educational reform in New York State. Mr. Sullivan is a graduate of Vanderbilt University.

Theresa Frangiosa
Board Secretary

View Bio

Theresa Frangiosa

Board Secretary

Board Member, Secretary, Theresa Frangiosa held executive positions in the pharmaceutical industry over a 25 year career before establishing Frangiosa and Associates, LLC in 2013, where she serves as Principal and Chief Executive Officer and provides guidance on a broad range of strategic decisions, integrating expertise into product and disease strategies, medical and scientific communications and patient and caregiver advocacy efforts. Her interest in Advocacy has resulted in long-standing support of several organizations dedicated to patient support in Brain Disorders and Breast Cancer and she participates on several Boards.

Her husband is a retired Navy Captain (Judge Advocate General’s Corps), and she was a long-time Dementia patient caregiver for her mother who had Alzheimer’s Disease. In addition to her service with UsAgainstAlzheimer’s, Ms. Frangiosa serves on the Board of Schizophrenia and Related Disorders Alliance of America (SARDAA).

Ms. Frangiosa has proven success demonstrated in a career as a Pharmaceutical Executive that spanned 25 years. In her roles within Pharma, she was a Global Launch Leader as well as overseeing Early Commercial Strategy in Neurosciences. She led large scale teams, cross-functional teams to define disease and therapeutic area strategies for Janssen and GlaxoSmithKline. She has also led indication prioritization efforts and development of over 200 Target Product Profiles over a variety of disease states, leveraging well-established processes and frameworks, including deeper understanding of patient journeys to create key insights.

She has applied her professional career experience and her passion for advocacy to help create a channel for feedback from those diagnosed with or at risk for Alzheimer’s Disease or Dementia, their care partners and individuals who are ‘worried well’, called the A-LIST. She is the lead investigator for this research study with IRB oversight.

Ms. Frangiosa obtained her Bachelor of Administration, Accounting Concentration from Ursinus College (Collegeville, PA) in 1988 and her Masters of Business Administration, Pharmaceutical Marketing from St. Joseph’s University in 1996.

David M. Biondi, DO, FAAN
Board Member

View Bio

David M. Biondi, DO, FAAN

Board Member

David Biondi received his medical degree from the University of New England, College of Osteopathic Medicine in Biddeford ME. He completed residency training in Neurology at the National Naval Medical Center in Bethesda MD and is board-certified in Neurology with subspecialty expertise in Headache and Pain Medicine. He received his Bachelor of Science – Magna Cum Laude in Pharmacy from the Long Island University, Schwartz College of Pharmacy & Health Science in Brooklyn NY.

Dr. Biondi has over 15 years of experience in clinical research and development of pharmaceuticals and medical devices in the neurology, psychiatry, and pain therapeutic areas. His experiences include the design, implementation, monitoring, and interpretation of phase 2 to phase 4 clinical trials and in-house and field-based activities associated with insights generation, new business opportunities, emerging health policy, knowledge translation and implementation, and organizational effectiveness. He previously served as Executive Director for Clinical Programs with Cohen Veterans Bioscience.

Dr. Biondi has over 20 years of clinical experience in medical practice and held medical directorships at the US Naval Hospital in Okinawa Japan, the Pain Management Program & Headache Institute at Maryview Medical Center in Portsmouth VA, the Pain Division of the Michigan Head Pain & Neurological Institute in Ann Arbor MI, and the Interdisciplinary Headache & Pain Rehabilitation Program at Spaulding Rehabilitation Hospital in Boston MA. He was previously an Assistant Neurologist at the Massachusetts General Hospital and an Instructor in Neurology at Harvard Medical School.

Dr. Biondi served as a trustee for the University of New England and was Chair of its Academic and Research Affairs committee and Vice-Chair of its Long-Range Planning committee. He also served as a Director and medical advisor for the After Action Network, a nonprofit Veteran Service Organization in Kansas City MO. He is a Fellow of the American Academy of Neurology.

Dave DeMarco, PhD
Board Member

View Bio

Dave DeMarco, PhD

Board Member

Dr. Dave DeMarco is a senior advisor to C-suite leaders in the Life Sciences and Healthcare industries. He serves as Chief Strategy Officer for Material Health Strategies and works with c-suite executives on growth strategies and team performance in both the for-profit and non-for-profit industries. He previously served as Chair of the Board of the American Diabetes Association, led Ernst & Young’s (EY’s) Northeast Life Sciences practice and was the Deputy Leader of the US Healthcare Practice.

With over 25 years of leadership experience, Dave advises, coaches and shares insights on strategy and transformation, commercial operations, hHealthcare policy, governance, public-private-partnerships, and entrepreneurial growth.

While serving on the board of the American Diabetes Association, he led Board initiatives involving: CEO succession, Principal Officer succession, Board Development, Policy creation, strategic plan implementation and technology partnerships.

Dave has held key executive positions, including: Global Aesthetic Franchise Leader, Sanofi Aventis; US Health Deputy Leader, Northeast Region Life Sciences Practice Leader and Johnson & Johnson Global Client Services Partner, EY; Research Scientist, Internal Venture Leader, Amoco Chemical; and cofounder, Idea Connection Systems.

Dave worked closely with the Aventis NA leadership team to develop post-merger integration growth strategies and launch key blockbuster products aimed at, and succeeding in, doubling the size of the business in four years. As a senior partner in EY’s Global Life Sciences team, Dave piloted a new P&L accountable, go-to-market model, growing the Northeast practice at 30% CAGR, resulting in a $400 million business. In his service to Johnson & Johnson, he partnered with J&J leadership in developing Janssen Healthcare Innovation, charged with creating future business units. Dave led the transformation of EY’s US Health practice, resulting in a $750 million business. As a member of the Sanofi Aventis NA Dermatology leadership team, Dave developed the global aesthetic franchise strategy and served as the commercial head for Europe. For this turnaround project, he created a plan to triple EBITDA, implement new global pricing policies and double customer acquisition.

Dave received his B.S. from Grove City College and Ph.D. in chemistry from Purdue University.

Learn More About CVB